STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and more

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Pharmalittle: We’re reading about a GSK deal for a drug from China, job losses in the U.S., and moreWorldPing
Image via STAT.

What happened

GSK has continued its drive to bulk up its pipeline, taking global rights to a multiple myeloma treatment developed in China…

Key facts

  • Reported by STAT and published Tue, 15 Sep 2026 13:29:47 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Follow the story

Living hubs that keep updating as this story develops.

Related WorldPing coverage

Russia oil squeeze, China competition, Saudi pipeline shut: India's crude crunchWorldPing
Times of India

Russia oil squeeze, China competition, Saudi pipeline shut: India's crude crunch

Where does that leave India, a country that imports around 90% of its crude oil? If crude oil prices continue to rise due to global supply constraints and Russian crude discounts ebb, will India’s crude oil bill manage another hit within months?

Brief by WorldPing · Original reporting by Times of India